GoAI
Get started
TriSalus Life Sciences, Inc. logo

TriSalus Life Sciences, Inc.

TLSI

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$5.27

+$0.04 · +0.76%

Aug 21, 4:00 PM ET

Pre-market

$5.13

−$0.14 · -2.66%

Aug 24, 5:02 AM ET

TLSI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

77

Undervalued

Momentum

35

Weakening

Sentiment

54

Mixed

Risk resilience

38

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Mary T. Szela
Listed since
Feb 8, 2021
Employees
102

Market position

Day range

Current $5.27

52-week range

Current $5.27

Open
$5.19
Previous close
$5.23
Volume
98.69K
0.25× average
Average volume
392.37K
Average daily volume
Market cap
324.5M USD
Beta
0.43
Market reference 1
50-day average
$4.5494
+15.84% above average
200-day average
$4.8074
+9.62% above average

Financials

Financial snapshot

Latest / TTM

Financial health

Altman Z-score
-3.63
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends133%-54%-241%-427%Gross margin, FY2021: 85.80%Gross margin, FY2022: 81.79%Gross margin, FY2023: 85.93%Gross margin, FY2024: 86.06%Gross margin, FY2025: 84.57%Operating margin, FY2021: -286.06%Operating margin, FY2022: -293.91%Operating margin, FY2023: -294.28%Operating margin, FY2024: -122.88%Operating margin, FY2025: -59.68%Net margin, FY2021: -343.35%Net margin, FY2022: -380.60%Net margin, FY2023: -320.69%Net margin, FY2024: -112.92%Net margin, FY2025: -86.88%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 85.80%. Gross margin FY2022 81.79%. Gross margin FY2023 85.93%. Gross margin FY2024 86.06%. Gross margin FY2025 84.57%. Operating margin FY2021 -286.06%. Operating margin FY2022 -293.91%. Operating margin FY2023 -294.28%. Operating margin FY2024 -122.88%. Operating margin FY2025 -59.68%. Net margin FY2021 -343.35%. Net margin FY2022 -380.60%. Net margin FY2023 -320.69%. Net margin FY2024 -112.92%. Net margin FY2025 -86.88%.

Income trends

Revenue

45.15M USD+53.41%

Operating income

−26.95M USD+25.49%

Net income

−39.23M USD-18.04%
Income trends across reported periods55.6M USD13.8M USD−28.01M USD−69.81M USDRevenue, FY2021: 8.4M USDRevenue, FY2022: 12.4M USDRevenue, FY2023: 18.51M USDRevenue, FY2024: 29.43M USDRevenue, FY2025: 45.15M USDOperating income, FY2021: −24.03M USDOperating income, FY2022: −36.44M USDOperating income, FY2023: −54.48M USDOperating income, FY2024: −36.17M USDOperating income, FY2025: −26.95M USDNet income, FY2021: −28.85M USDNet income, FY2022: −47.19M USDNet income, FY2023: −59.36M USDNet income, FY2024: −33.23M USDNet income, FY2025: −39.23M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 8.4M USD. Revenue FY2022 12.4M USD. Revenue FY2023 18.51M USD. Revenue FY2024 29.43M USD. Revenue FY2025 45.15M USD. Operating income FY2021 −24.03M USD. Operating income FY2022 −36.44M USD. Operating income FY2023 −54.48M USD. Operating income FY2024 −36.17M USD. Operating income FY2025 −26.95M USD. Net income FY2021 −28.85M USD. Net income FY2022 −47.19M USD. Net income FY2023 −59.36M USD. Net income FY2024 −33.23M USD. Net income FY2025 −39.23M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue45.15M USD29.43M USD18.51M USD12.4M USD8.4M USD
Cost of goods sold6.97M USD4.1M USD2.61M USD2.26M USD1.19M USD
Gross profit38.19M USD25.33M USD15.91M USD10.14M USD7.21M USD
Research and development14.97M USD17.69M USD29.84M USD21.36M USD14.22M USD
Selling, general, and administrative50.17M USD43.81M USD40.55M USD25.22M USD17.02M USD
Operating expenses65.13M USD61.49M USD70.38M USD46.58M USD31.24M USD
Interest income555K USD404K USD431K USD180K USD—
Interest expense5.54M USD3.09M USD16K USD1K USD1.76M USD
Depreciation and amortization626K USD744K USD684K USD414K USD464K USD
Operating income−26.95M USD−36.17M USD−54.48M USD−36.44M USD−24.03M USD
Net income−39.23M USD−33.23M USD−59.36M USD−47.19M USD−28.85M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 7 misses, 1 met estimate
Average EPS surprise
-62.38%
11 comparable reports
Latest EPS result
-0.16
Estimate -0.16 · Miss by 3.23%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.11-0.41-0.72-1.03Q1 '25MetQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -0.35, estimate -0.35, surprise 0.00%, Met estimate. Q2 2025, reported May 15, 2025: actual -0.33, estimate -0.2, surprise -65.00%, Miss. Q3 2025, reported Aug 12, 2025: actual -0.27, estimate -0.22, surprise -22.73%, Miss. Q4 2025, reported Nov 13, 2025: actual -0.96, estimate -0.17, surprise -464.71%, Miss. Q1 2026, reported Mar 5, 2026: actual -0.21, estimate -0.13, surprise -61.54%, Miss. Q2 2026, reported May 12, 2026: actual -0.33, estimate -0.16, surprise -106.25%, Miss. Q3 2026, reported Aug 6, 2026: actual -0.16, estimate -0.155, surprise -3.23%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.124, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates14.58M12.24M9.9M7.56MQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual 8.26M USD, estimate 8.12M USD, surprise +1.79%, Beat. Q2 2025, reported May 15, 2025: actual 9.17M USD, estimate 9.09M USD, surprise +0.79%, Beat. Q3 2025, reported Aug 12, 2025: actual 11.21M USD, estimate 11.65M USD, surprise -3.76%, Miss. Q4 2025, reported Nov 13, 2025: actual 11.57M USD, estimate 13.2M USD, surprise -12.38%, Miss. Q1 2026, reported Mar 5, 2026: actual 13.21M USD, estimate 12.82M USD, surprise +3.04%, Beat. Q2 2026, reported May 12, 2026: actual 8.9M USD, estimate 10.19M USD, surprise -12.67%, Miss. Q3 2026, reported Aug 6, 2026: actual 11.41M USD, estimate 10.27M USD, surprise +11.10%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate 14.02M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$8.00

51.80% upside
Past 12 months12-month forecastHigh $8.00Average $8.00Low $8.00

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy3100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

3 institutions
Lake StreetmaintainBuy
Roth MKMmaintainBuy

TLSI news

marketbeat.com

TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference

TriSalus Life Sciences NASDAQ: TLSI outlined its commercial expansion, product pipeline and clinical-evidence strategy during Canaccord Genuity's Global Growth Conference, with management emphasizing the company's…

Read source
marketbeat.com

TriSalus Life Sciences Q2 Earnings Call Highlights

TriSalus Life Sciences NASDAQ: TLSI reported second-quarter revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, as demand for its TriNav pressure-enabled drug delivery system increased. The company…

Read source
seekingalpha.com

TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript

TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript

Read source
businesswire.com

TriSalus Life Sciences Reports Second Quarter 2026 Results

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic…

Read source
businesswire.com

TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform…

Read source
businesswire.com

TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational…

Read source

TLSI peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TLSI

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
5.75M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
5.18M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.48M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
2.35M
Weight
0.02%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.22M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
866.46K
Weight
0.06%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Vanguard Russell 2000 Growth ETF logoVanguard Russell 2000 Growth ETFVTWG
Market value
235.51K
Weight
0.01%
AUM
1.7B USD
Expense ratio
0.06%
Price / 1D
$282.73+1.21%
Invesco NASDAQ Future Gen 200 ETF logoInvesco NASDAQ Future Gen 200 ETFQQQS
Market value
171.71K
Weight
0.76%
AUM
22.98M USD
Expense ratio
0.20%
Price / 1D
$45.0826+1.10%

Continue in GoAI

Research TLSI

research.disclaimer